Search This Blog

Wednesday, February 25, 2026

Celldex completes global Phase 3 enrollment six months early

 in EMBARQ-CSU1 and EMBARQ-CSU2 barzolvolimab trials for chronic spontaneous urticaria

https://finviz.com/quote.ashx?t=CLDX&p=d

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)